Comparative Pharmacology
Head-to-head clinical analysis: FOSAMPRENAVIR CALCIUM versus LEXIVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOSAMPRENAVIR CALCIUM versus LEXIVA.
FOSAMPRENAVIR CALCIUM vs LEXIVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fosamprenavir is a prodrug of amprenavir, an HIV-1 protease inhibitor. It binds to the active site of HIV-1 protease, preventing cleavage of viral Gag-Pol polyproteins, resulting in immature, non-infectious viral particles.
Fosamprenavir is a prodrug of amprenavir, a protease inhibitor (PI) that competitively inhibits HIV-1 protease, preventing cleavage of viral Gag-Pol polyprotein, resulting in immature, non-infectious viral particles.
1400 mg orally twice daily or 1400 mg once daily plus ritonavir 100 mg or 200 mg once daily plus ritonavir 100 mg. Alternatively, fosamprenavir 700 mg plus ritonavir 100 mg twice daily.
1400 mg orally twice daily (with ritonavir 100 mg) or 1400 mg orally once daily (with ritonavir 100 mg and cobicistat 150 mg). For treatment-naïve patients, 1400 mg orally once daily with ritonavir 100 mg or cobicistat 150 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 7.7 hours; supports twice-daily dosing.
Terminal elimination half-life is 2.8 to 5.7 hours; with ritonavir boosting, half-life increases to 7-10 hours, allowing once-daily dosing.
Primarily hepatic metabolism via CYP3A4, with 14% renal excretion of unchanged drug; 68% fecal, 1% urinary as unchanged drug.
Renal (approximately 82% in urine, with 14% as parent drug and 68% as metabolites); fecal (approximately 16%, with 7% as parent drug).
Category A/B
Category C
Protease Inhibitor
Protease Inhibitor